Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics symbols : Akba save search
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-02 (Crawled : 20:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: -6.29%
nasdaq grants therapeutics
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Published: 2024-03-28 (Crawled : 07:00) - prnewswire.com
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: 0.91%
H: 3.1%
C: -0.39%
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approved treatment
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Published: 2024-03-28 (Crawled : 01:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approval treatment dialysis
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-11 (Crawled : 21:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -2.07%
report year therapeutics financial results
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-02 (Crawled : 21:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
ZVRA | $4.515 0.33% 0.33% 360K
|
n/a
|
| O: 0.42%
H: 3.33%
C: 2.83%
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -1.2%
H: 7.46%
C: 5.65%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.62%
H: 11.66%
C: 9.82%
therapeutics financial
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
Published: 2024-01-09 (Crawled : 14:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: -1.89%
commercial therapeutics
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 22:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 1.57%
H: 6.98%
C: 6.2%
nasdaq grants therapeutics
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.84%
H: 2.5%
C: 0.0%
conference therapeutics
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-01 (Crawled : 21:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
Published: 2023-11-20 (Crawled : 13:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.0%
H: 6.0%
C: 2.0%
conference therapeutics
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Published: 2023-11-08 (Crawled : 12:30) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: -5.5%
H: 3.88%
C: -6.8%
business therapeutics financial results
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-11-01 (Crawled : 20:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.91%
H: 5.62%
C: -0.73%
nasdaq grants therapeutics
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Published: 2023-10-31 (Crawled : 20:00) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 1.5%
H: 4.82%
C: 2.5%
report business therapeutics financial results
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Published: 2023-10-25 (Crawled : 13:00) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: -0.82%
H: 3.51%
C: -5.88%
fda disease kidney resubmission anemia treatment
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: -0.08%
H: 3.56%
C: -4.39%
kidney week therapeutics
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-10-03 (Crawled : 20:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.95%
H: 8.49%
C: 4.72%
nasdaq grants therapeutics
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
Published: 2023-09-26 (Crawled : 17:00) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.88%
H: 9.65%
C: 2.63%
vafseo australia approval update commercial
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference - September 6, 2023
Published: 2023-09-06 (Crawled : 14:30) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 1.64%
H: 6.45%
C: 0.81%
conference global therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
OSK 4 | $117.72 0.05% 1.96% 370K
|
Producer Manufacturing
HYLN 4 | $1.29 -2.27% 1.55% 680K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.